Regulatory News:
Pursuant to the liquidity contract entrusted to Invest Securities by NOXXON PHARMA (Paris:ALNOX), on 31 December 2016 the following assets appeared on the liquidity account:
- Number of shares: 10,770
- Cash balance of the liquidity account: € 83,219.
As a reminder, at the time of the last half-yearly report on 30 June 2016, the following resources were booked to the liquidity account:
- Number of shares: 10,000
- Cash balance of the liquidity account: €100,000
About NOXXON
NOXXON Pharma N.V. is a clinical-stage
biopharmaceutical company focused on cancer treatment. NOXXON’s goal is
to significantly enhance the effectiveness of cancer treatments
including immuno-oncology approaches (such as immune checkpoint
inhibitors) and current standards of care (such as chemotherapy and
radiotherapy). NOXXON’s Spiegelmer® platform has
generated a proprietary pipeline of clinical-stage product candidates
including its lead cancer drug candidate NOX-A12, which is the subject
of a clinical immuno-oncology collaboration agreement with Merck & Co. /
MSD (NYSE: MRK) to study NOX-A12 combined with Keytruda®
(pembrolizumab) in pancreatic and colorectal cancer. NOXXON is supported
by a strong group of leading international investors, including TVM
Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners,
DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, The
Netherlands and its office in Berlin, Germany. Further information can
be found at: www.noxxon.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170106005035/en/